Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study

INTRODUCTION: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG + 3TC) are well tolerated and effective in clinical trials. This study aimed to evaluate the safety and efficacy of these two schemes in a real-world setting and to obtain the first data...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Lin, Xie, Xiaoxin, Fu, Yanhua, Yang, Xiaoyan, Ma, Shujing, Kong, Linghong, Song, Chunli, Song, Yebing, Ren, Tingting, Long, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651567/
https://www.ncbi.nlm.nih.gov/pubmed/37845566
http://dx.doi.org/10.1007/s40121-023-00879-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651567/
https://www.ncbi.nlm.nih.gov/pubmed/37845566
http://dx.doi.org/10.1007/s40121-023-00879-x

Ejemplares similares